Fund Holdings — Lion Point Capital, LP

Total Portfolio Value:
$31.94M
Total Bought:
$6.60M
Total Sold:
$24.13M
Net Transaction:
-$17.53M
Notable People:
Carl Didric Marcus Cederholm
Securities
▲▼
SharesValue
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Ardelyx Inc1,046,667856,667-190,000$7.64M$6.35M19.87%-$1.29M
Insmed Incorporated(INSM)70,33570,3350$1.91M$4.71M14.75%+$2.80M
Milestone Pharmaceuticals Inc.(MIST)2,300,2072,340,207+40,000$4.12M$3.09M9.67%-$1.03M
Geron Corporation(GERN)600,000630,000+30,000$1.98M$2.67M8.36%+$691.2K
Marinus Pharmaceuticals Inc2,119,1362,114,827-4,309$19.16M$2.47M7.75%-$16.68M
Kiniksa Pharmaceuticals International, plcCL A(KNSA)0104,691+104,691$0$1.95M6.12%+$1.95M
Syndax Pharmaceuticals, Inc.(SNDX)65,00065,0000$1.55M$1.33M4.18%-$212.6K
BridgeBio Pharma, Inc.(BBIO)049,000+49,000$0$1.24M3.89%+$1.24M
Avadel Pharmaceuticals Plc082,500+82,500$0$1.16M3.63%+$1.16M
Neurocrine Biosciences, Inc.(NBIX)7,5008,350+850$1.03M$1.15M3.60%+$115.1K
Fennec Pharmaceuticals Inc.(FENC)170,000170,0000$1.89M$1.04M3.25%-$851.7K
Mineralys Therapeutics, Inc.(MLYS)60,00079,000+19,000$774.6K$924.3K2.89%+$149.7K
Enphys Acquisition CorpCL A78,12578,1250$845.3K$857.8K2.69%+$12.5K
Jasper Therapeutics, Inc.(JSPR)32,00032,0000$939.5K$726.4K2.27%-$213.1K
Bluebird Bio Inc848,256678,256-170,000$1.09M$667.5K2.09%-$418.2K
Burgerfi International Inc2,745,9382,745,9380$1.59M$557.4K1.75%-$1.03M
REGENXBIO Inc.(RGNX)32,50036,250+3,750$684.8K$424.1K1.33%-$260.6K
Seres Therapeutics, Inc.(MCRB)340,761340,7610$263.8K$246.6K0.77%-$17.1K
Lumos Pharma Inc90,79490,7940$256.0K$210.6K0.66%-$45.4K
Microsoft Corporation(MSFT)1001000$42.1K$44.7K0.14%+$2.6K
Spruce Biosciences Inc75,00075,0000$58.9K$38.8K0.12%-$20.1K
Burgerfi International IncW EXP 12 16 2022,083,4382,083,4380$81.3K$26.3K0.08%-$55.0K
Battalion Oil Corporation(BATL)19,9267,423-12,503$112.8K$24.8K0.08%-$88.0K
Alphabet Inc.CL C(GOOG)1001000$15.2K$18.3K0.06%+$3.1K
Avadel Pharmaceuticals PlcADR82,5000-82,500$1.39M$0—-$1.39M
Humacyte, Inc.(HUMA)235,0000-235,000$730.9K$0—-$730.9K
Kiniksa Pharmaceuticals LtdCL A130,6910-130,691$2.58M$0—-$2.58M
Replimune Group, Inc.(REPL)42,5000-42,500$347.2K$0—-$347.2K
Semtech Corporation(SMTC)140-14$385$0—-$385
Travere Therapeutics, Inc.(TVTX)78,0000-78,000$601.4K$0—-$601.4K
Travere Therapeutics, Inc.NOTE 2 250 3 0(TVTX)000$629.5K$0—-$629.5K
Page 1 of 1
Lion Point Capital, LP — 13F Holdings — Q2 2024 | TickerTrail